HOUSTON, Jan. 20, 2022 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"),
a biopharmaceutical company specializing in the development of
novel treatments for primary and metastatic cancers in the brain
and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS
Pharmaceuticals, will participate in the Virtual Investor 2022 Top
Picks Conference on Wednesday, January 26,
2022 at 11:00 AM ET.
As part of the virtual event, the Company will provide a
corporate presentation, followed by a moderated interactive Q&A
session. In addition to the moderated portion of the event, all
investors and interested parties will have the opportunity to
submit questions live during the event. Interested parties may also
pre-submit questions in advance of the live event, which can be
sent via the conference website at virtualinvestorco.com. The
Company will answer as many questions as possible during the
A live video webcast of the presentation will be available
on the Events page of the Investors section of the
Company's website (cnspharma.com). A webcast replay will be
available two hours following the live presentation and will be
accessible for one year.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The Company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of its
WP1244 drug technology, which utilizes anthracycline and
distamycin-based scaffolds to create small molecule agents and is
believed to be 500x more potent than daunorubicin in inhibiting
tumor cell proliferation. Preclinical studies of WP1244
demonstrated high uptake in the brain with antitumor activity. CNS
Pharmaceuticals is evaluating the use of WP1244 in the treatment of
brain cancers, pancreatic, ovarian, and lymphomas.
For more information, please visit www.CNSPharma.com, and
connect with the Company on Twitter, Facebook, and LinkedIn.
View original content to download
SOURCE CNS Pharmaceuticals, Inc.